Xellia spent $200M and 5 years to fix up former Boehringer site in Cleveland. Now, it's up and running again

SourceFierce Pharma
Date Published08/17/2021
Author NameFraiser Kansteiner
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Xellia Pharmaceuticals
Parent companyNovo Holdings A/S
Type of work Manufacturing
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):300
Year reshoring announced:2015
Year reshoring implemented or to be implemented:2021
Capital investment ($):200
Country(ies) from which reshored:Denmark
City reshored to:Cleveland
State(s) reshored to:OH
If relevant, work nearshored to:-
Product(s) reshoredlyophilized vancomycin, sterile injectables
What domestic positive factors made reshoring more attractive?Proximity to customers/market, Other, Covid-19
Find Reshoring Articles